{
    "organizations": [],
    "uuid": "23184d5768826a5e6865dde564a7ee2ba8a063d1",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/01/globe-newswire-xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-first-quarter-2018-financial-results-and-provide.html",
    "ord_in_thread": 0,
    "title": "Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide Corporate Update",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "BURNABY, British Columbia, May 01, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, May 8, 2018. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.\nTo participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4982979. The webcast will be broadcast live on the “Investors” section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days.\nAbout Xenon Pharmaceuticals Inc.\nXenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as epilepsy, migraine and pain. For more information, please visit www.xenon-pharma.com .\n“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.\nInvestor/Media Contact :\nJodi Regts\nVice President, Corporate Affairs & Investor Relations\nXenon Pharmaceuticals Inc.\nPhone: 604.484.3353\nEmail: investors@xenon-pharma.com\nSource:Xenon Pharmaceuticals Inc.",
    "published": "2018-05-02T00:01:00.000+03:00",
    "crawled": "2018-05-02T02:06:09.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "burnaby",
        "british",
        "columbia",
        "may",
        "globe",
        "newswire",
        "xenon",
        "pharmaceutical",
        "nasdaq",
        "xene",
        "biopharmaceutical",
        "company",
        "today",
        "announced",
        "report",
        "first",
        "quarter",
        "financial",
        "operating",
        "result",
        "close",
        "financial",
        "market",
        "tuesday",
        "may",
        "xenon",
        "management",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "pm",
        "eastern",
        "time",
        "pm",
        "pacific",
        "time",
        "discus",
        "result",
        "provide",
        "corporate",
        "update",
        "participate",
        "call",
        "please",
        "dial",
        "international",
        "caller",
        "provide",
        "conference",
        "id",
        "number",
        "webcast",
        "broadcast",
        "live",
        "investor",
        "section",
        "xenon",
        "website",
        "available",
        "replay",
        "following",
        "call",
        "day",
        "xenon",
        "pharmaceutical",
        "xenon",
        "clinical",
        "stage",
        "biopharmaceutical",
        "company",
        "focused",
        "developing",
        "innovative",
        "therapeutic",
        "improve",
        "life",
        "patient",
        "neurological",
        "disorder",
        "building",
        "upon",
        "extensive",
        "knowledge",
        "human",
        "genetics",
        "disease",
        "caused",
        "mutation",
        "ion",
        "channel",
        "known",
        "channelopathies",
        "advancing",
        "independently",
        "pharmaceutical",
        "collaborator",
        "novel",
        "product",
        "pipeline",
        "ion",
        "channel",
        "modulators",
        "address",
        "therapeutic",
        "area",
        "high",
        "unmet",
        "medical",
        "need",
        "epilepsy",
        "migraine",
        "pain",
        "information",
        "please",
        "visit",
        "xenon",
        "xenon",
        "logo",
        "registered",
        "trademark",
        "trademark",
        "xenon",
        "pharmaceutical",
        "various",
        "jurisdiction",
        "trademark",
        "belong",
        "respective",
        "owner",
        "contact",
        "jodi",
        "regts",
        "vice",
        "president",
        "corporate",
        "affair",
        "investor",
        "relation",
        "xenon",
        "pharmaceutical",
        "phone",
        "email",
        "investor",
        "source",
        "xenon",
        "pharmaceutical",
        "inc"
    ]
}